HLA Alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Haskelberg, Hila ^a   Cordery, Damien V ^a   Amin, Janaki ^a   Kelleher, Anthony D ^a,b   Cooper, David A ^a,b   Emery, Sean ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b St Vincent's Centre for Applied Medical Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 1 A24; HLA ANTIGEN CLASS 1 AO2; HLA ANTIGEN CLASS 1 B07; HLA ANTIGEN CLASS 2; HLA ANTIGEN CLASS 2 DQ3; HLA ANTIGEN CLASS 2 DR9; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR, LAMIVUDINE DRUG COMBINATION; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG COMBINATION; EMTRICITABINE; HLA DQ ANTIGEN; HLA-DQ3 ANTIGEN; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ALLELE; ARTICLE; BONE DENSITY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; PROCEDURES;

ADENINE; ADULT; ALLELES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HLA-DQ ANTIGENS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES;

EID: 84899868121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093333     Document Type: Article

References (29)

1. Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: 292-304.
2. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, et al. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309. (Pubitemid 129516268)
3. Gratacos J, Collado A, Pons F, Osaba M, Sanmarti R, et al. (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis & Rheumatism 42: 2319-2324. (Pubitemid 30333411)
4. Slemenda C, Turner C, Peacock M, Christian J, Sorbel J, et al. (1996) The genetics of proximal femur geometry, distribution of bone mass and bone mineral density. Osteoporosis international 6: 178-182. (Pubitemid 26099843)
5. Arden N, Baker J, Hogg C, Baan K, Spector T (1996) The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. Journal of Bone and Mineral Research 11: 530-534. (Pubitemid 26109073)
6. Roshandel D, Holliday KL, Pye SR, Boonen S, Borghs H, et al. (2010) Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men. Journal of Bone and Mineral Research 25: 1830-1838.
7. Tsuji S, Munkhbat B, Hagihara M, Tsuritani I, Abe H, et al. (1998) HLA-A*24-B*07-DRB1*01 Haplotype Implicated with Genetic Disposition of Peak Bone Mass in Healthy Young Japanese Women. Human immunology 59: 243-249. (Pubitemid 28176423)
8. Richards JB, Zheng H-F, Spector TD (2012) Genetics of osteoporosis from genome-wide association studies: advances and challenges. Nature Reviews Genetics 13: 576-588.
9. Douroudis K, Tarassi K, Athanassiades T, Giannakopoulos F, Kominakis A, et al. (2007) HLA alleles as predisposal factors for postmenopausal osteoporosis in a Greek population. Tissue antigens 69: 592-596. (Pubitemid 46733685)
10. Papet I, El Yousfi M, Godin J, Mermoud A, Davicco M, et al. (2008) HLA-B27 rats develop osteopaenia through increased bone resorption without any change in bone formation. J Musculoskelet Neuronal Interact 8: 251-256.
11. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, et al. (1999) HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283: 1748-1752.
12. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, et al. (2005) AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nature medicine 11: 1290-1292. (Pubitemid 41752907)
13. Mallal S, Nolan D, Witt C, Masel G, Martin AM, et al. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. The Lancet 359: 727-732. (Pubitemid 34215071)
14. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, et al. (2009) HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenetics and genomics 19: 139.
15. Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, Kiertiburanakul S, Charoenyingwattana A, et al. (2010) Association between HLA-B*4001 and Lipodystrophy among HIV-Infected Patients from Thailand Who Received a Stavudine-Containing Antiretroviral Regimen. Clinical Infectious Diseases 50: 597-604.
16. Domingo P, Mateo MG, Pruvost A, Torres F, Salazar J, et al. (2013) Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40: 01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients. PloS one 8: e67035.
17. Cordery DV, Martin A, Amin J, Kelleher AD, Emery S, et al. (2012) The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV. AIDS 26: 2337-2344.
18. Haskelberg H, Hoy JF, Amin J, Ebeling PR, Emery S, et al. (2012) Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS One 7: e38377.
19. Martin A, Bloch M, Amin J, Baker D, Cooper DA, et al. (2009) Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clinical Infectious Diseases 49: 1591.
20. Sidney J, Peters B, Frahm N, Brander C, Sette A (2008) HLA class I supertypes: a revised and updated classification. BMC immunology 9: 1.
21. Doytchinova IA, Flower DR (2005) In silico identification of supertypes for class II MHCs. The Journal of Immunology 174: 7085-7095. (Pubitemid 40705674)
22. Hsu Y-H, Niu T, Terwedow H, Xu X, Feng Y, et al. (2006) Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Human Genetics 118: 568-577. (Pubitemid 41825129)
23. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337-342. (Pubitemid 40852708)
24. LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, et al. (2004) Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. European journal of immunology 34: 1513-1525.
25. Kim JH, Kim K, Youn BU, Jin HM, Kim N (2010) MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR. Cellular signalling 22: 1341-1349.
26. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, et al. (2008) Multiple genetic loci for bone mineral density and fractures. New England Journal of Medicine 358: 2355-2365. (Pubitemid 351749159)
27. Estrada K, Styrkarsdottir U, Evangelou E, Hsu Y-H, Duncan EL, et al. (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature genetics 44: 491-501.
28. Hajeer AH, Hutchinson IV (2001) Influence of TNFα gene polymorphisms on TNFα production and disease. Human immunology 62: 1191-1199. (Pubitemid 33032271)
29. Steeve KT, Marc P, Sandrine T, Dominique H, Yannick F (2004) IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine & growth factor reviews 15: 49-60. (Pubitemid 38121290)